Effect of obesity, dyslipidemia, and diabetes on trastuzumab-related cardiotoxicity in breast cancer
P Kosalka, C Johnson, M Turek, J Sulpher, A Law… - Current …, 2019 - mdpi.com
Background: Clinical trials have demonstrated an increased risk of cardiotoxicity in patients
with breast cancer (BCA) receiving trastuzumab-based therapy. Diabetes, dyslipidemia, and …
with breast cancer (BCA) receiving trastuzumab-based therapy. Diabetes, dyslipidemia, and …
Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single “real-world” setting
Management of human epidermal growth factor receptor-2-positive (HER2+) breast cancer
patients includes the combination of adjuvant chemotherapy and trastuzumab. A meta …
patients includes the combination of adjuvant chemotherapy and trastuzumab. A meta …
Risk factors for developing cardiotoxicity of trastuzumab in breast cancer patients: an observational single-centre study
M Gunaldi, BB Duman, CU Afsar… - Journal of Oncology …, 2016 - journals.sagepub.com
Background Trastuzumab is a recombinant humanized monoclonal antibody used to treat
human epidermal growth factor receptor 2 positive breast cancer, with recognized …
human epidermal growth factor receptor 2 positive breast cancer, with recognized …
Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: a meta-analysis
Z Jawa, RM Perez, L Garlie, M Singh, R Qamar… - Medicine, 2016 - journals.lww.com
Background: Trastuzumab targets the human epidermal growth factor receptor 2 oncogene
and in combination with first-line therapy results in significantly improved survival outcomes …
and in combination with first-line therapy results in significantly improved survival outcomes …
Conventional cardiac risk factors associated with trastuzumab-induced cardiotoxicity in breast cancer: Systematic review and meta-analysis
G Koulaouzidis, AE Yung, DE Yung… - Current Problems in …, 2021 - Elsevier
Background: Trastuzumab has had a major impact on the treatment of human epidermal
growth factor receptor 2 (HER2) positive breast cancer patients. However, it is associated …
growth factor receptor 2 (HER2) positive breast cancer patients. However, it is associated …
Incidence, diagnosis, and treatment of cardiac toxicity from trastuzumab in patients with breast cancer
S Nowsheen, PV Viscuse, CC O'Sullivan… - Current breast cancer …, 2017 - Springer
Abstract Purpose of Review Treatment with trastuzumab is a cornerstone of human
epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer treatment, but …
epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer treatment, but …
Trastuzumab-induced cardiotoxicity and its risk factors in real-world setting of breast cancer patients
T Moilanen, A Jokimäki, O Tenhunen… - Journal of Cancer …, 2018 - Springer
Purpose Cardiotoxicity is the most important side effect of trastuzumab treatment. Heart
function monitoring is recommended during the treatment which has led to growing use of …
function monitoring is recommended during the treatment which has led to growing use of …
Trastuzumab-induced cardiotoxicity: testing a clinical risk score in a real-world cardio-oncology population
M Rushton, C Johnson, S Dent - Current Oncology, 2017 - mdpi.com
Background: Trastuzumab has improved survival for women with HER2-positive breast
cancer, but its use is associated with an increased risk of cardiotoxicity. With increased …
cancer, but its use is associated with an increased risk of cardiotoxicity. With increased …
Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis
T Chen, T Xu, Y Li, C Liang, J Chen, Y Lu, Z Wu… - Cancer treatment …, 2011 - Elsevier
BACKGROUND: Trastuzumab is used widely for the treatment of early and advanced breast
cancer. However, concerns have arisen regarding its cardiac toxicity. We did a systematic …
cancer. However, concerns have arisen regarding its cardiac toxicity. We did a systematic …
Risks of trastuzumab‐related cardiotoxicity in breast cancer patients in Taiwan
Abstract Aims In contrast to Western patients with breast cancer, Asian patients are relatively
younger at diagnosis, and most are free from traditional cardiovascular risk factors. Despite …
younger at diagnosis, and most are free from traditional cardiovascular risk factors. Despite …